Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Thrombocytopenia 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Colorectal Neoplasms 1

Interventions

Imatinib Mesylate 60Cyclophosphamide 57fludarabine phosphate 51fludarabine 43Whole-Body Irradiation 41Mycophenolic Acid 41Tacrolimus 33nilotinib 31Dasatinib 31Busulfan 29Peripheral Blood Stem Cell Transplantation 23Cyclosporine 22Melphalan 21Thiotepa 20Granulocyte Colony-Stimulating Factor 19Filgrastim 18thymoglobulin 17Cytarabine 17Antilymphocyte Serum 15Stem Cell Transplantation 14sargramostim 13Methotrexate 13ponatinib 12asciminib 10Cyclosporins 10Cord Blood Stem Cell Transplantation 10bosutinib 9Rituximab 9Interferon-alpha 9Clofarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × oprelvekin × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡